Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

Stock Information for Sagimet Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sagimet Biosciences Inc.

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.